Dr Reddy’s has had its request for a US Food and DrugAdministration (FDA) reinspection of its oncology formulations plant in Duvvada, India, granted by the US agency. As Generics bulletin went to press, eight ‘Form 483’ observations were announced.
Earlier this year, Dr Reddy’s asked the FDA to schedule an inspection as part of ongoing efforts to resolve agency...







